Uwe Christians

Dr. Uwe Christians

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ALAbbie D. Leino
Abbie D. Leino
EKEileen C. King
Eileen C. King
WJWenlei Jiang
Wenlei Jiang
AVAlexander A. Vinks
Alexander A. Vinks
JKJost Klawitter
Jost Klawitter
Jennifer M. RohanJennifer M. Rohan
Jennifer M. Rohan
The purpose of this study was to determine the intra‐patient (within the same patient) variability of tacrolimus in adherent patients. Daily tacrolimus trough levels were obtained at home using dried blood spot technology in kidney and liver transplant recipients. Patients were randomized to receive 3 formulations of tacrolimus, each for two 1‐week periods. Adherence was monitored by patient diary, pill counts, and use of the Medication Event Monitoring System (MEMS). Variability was quantified as the coefficient of variation (CV). Comparison of CV between groups was by independent t‐test or one‐way ANOVA as appropriate. The population was found to be adherent with a rate of 99.9% with a mean interval between the evening and morning dose of tacrolimus of 11.86 hours. The median CV for the entire population was 15.2% (range 4.8‐110%). There were no differences in CV by allograft type or tacrolimus formulation. The multivariate analysis did not identify any demographic characteristics associated with a CV>30%. In a highly adherent population, tacrolimus did not display high intra‐patient variability. Given the association between IPV and poor allograft outcomes future studies are needed to quantitate the influence of adherence and establish target IPV goals.

BMBrianna Moore
Brianna Moore
KSKaytlyn A. Salmons
Kaytlyn A. Salmons
AHAdrienne T. Hoyt
Adrienne T. Hoyt
KSKarli Swenson
Karli Swenson
EBEmily A. Bates
Emily A. Bates
DDDana Dabelea
Dana Dabelea
Background: Prenatal exposure to cannabis may influence childhood cognition and behavior, but the epidemiologic evidence is mixed. Even less is known about the potential impact of secondhand exposure to cannabis during early childhood. Objective: This study sought to assess whether prenatal and/or postnatal exposure to cannabis was associated with childhood cognition and behavior. Study design: This sub-study included a convenience sample of 81 mother–child pairs from a Colorado-based cohort. Seven common cannabinoids (including delta 9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD)) and their metabolites were measured in maternal urine collected mid-gestation and child urine collected at age 5 years. Prenatal and postnatal exposure to cannabis was dichotomized as exposed (detection of any cannabinoid) and not exposed. Generalized linear models examined the associations between prenatal or postnatal exposure to cannabis with the NIH Toolbox and Child Behavior Checklist T-scores at age 5 years. Results: In this study, 7% (n = 6) of the children had prenatal exposure to cannabis and 12% (n = 10) had postnatal exposure to cannabis, with two children experiencing this exposure at both time points. The most common cannabinoid detected in pregnancy was Δ9-THC, whereas the most common cannabinoid detected in childhood was CBD. Postnatal exposure to cannabis was associated with more aggressive behavior (β: 3.2; 95% CI: 0.5, 5.9), attention deficit/hyperactivity problems (β: 8.0; 95% CI: 2.2, 13.7), and oppositional/defiant behaviors (β: 3.2; 95% CI: 0.2, 6.3), as well as less cognitive flexibility (β: −15.6; 95% CI: −30.0, −1.2) and weaker receptive language (β: −9.7; 95% CI: −19.2, −0.3). By contrast, prenatal exposure to cannabis was associated with fewer internalizing behaviors (mean difference: −10.2; 95% CI: −20.3, −0.2) and fewer somatic complaints (mean difference: −5.2, 95% CI: −9.8, −0.6). Conclusions: Our study suggests that postnatal exposure to cannabis is associated with more behavioral and cognitive problems among 5-year-old children, independent of prenatal and postnatal exposure to tobacco. The potential risks of cannabis use (including smoking and vaping) during pregnancy and around young children should be more widely communicated to parents.

13 March 2024 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
TSTory R. Spindle
Tory R. Spindle
CZC. Austin Zamarripa
C. Austin Zamarripa
EREthan Russo
Ethan Russo
LPLauren Pollak
Lauren Pollak
GBGeorge Bigelow
George Bigelow
RVRyan Vandrey
Ryan Vandrey

21 November 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MHMatthijs W. Van Hoogdalem
Matthijs W. Van Hoogdalem
TJTrevor Nigel Johnson
Trevor Nigel Johnson
BMBrooks T. McPhail
Brooks T. McPhail
SKSuyog Kamatkar
Suyog Kamatkar
SWScott L. Wexelblatt
Scott L. Wexelblatt
Tomoyuki MizunoTomoyuki Mizuno
Tomoyuki Mizuno

1 September 2015 in Neuropharmacology
Verified
Journal Article
Closed access
KBKatharina Bösche
Katharina Bösche
KWKarin Weissenborn
Karin Weissenborn
Uwe ChristiansUwe Christians
Uwe Christians
OWOliver Witzke
Oliver Witzke
HEHarald Engler
Harald Engler
MHMartin Hadamitzky
Martin Hadamitzky

21 December 2017 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
JMJames S. McLay
James S. McLay
TEThomas Engelhardt
Thomas Engelhardt
BMBaba Sulemana Mohammed
Baba Sulemana Mohammed
GCGary Cameron
Gary Cameron
MCMindy N. Cohen
Mindy N. Cohen
BABrian J. Anderson
Brian J. Anderson